What India Inc can learn from Big Blue
IBM's global research head Arvind
Krishna on its patents factory, innovation engine and working with Nobel
laureates
About two decades ago, when Java was
synonymous with an Indonesian coffee bean rather than a computer program,
Arvind Krishna hopped from client to client, posing a fundamental question: “I
know you can work with lots of companies, but would you like to work with the
one where Tony Nadalin (who wrote the standard for Java security) can help you
crack your project?“ Back then, Krishna was more of a greenhorn at IBM, the
American technology and consulting giant headquartered in Armonk, New York with
revenues of $92.7 billion. Today, as Senior VP & Director of IBM Research,
the IIT-Kanpur alum with 15 patents under his belt, Krishna heads Research
& Development (R&D) for IBM. He's only the eleventh person to hold such
a position in the seven decades of IBM Research Labs.
So, what does Krishna's job entail?
For starters, IBM, also dubbed the
Big Blue for its size and the color of its logo and packaging, spent a
staggering $5.4 billion on R&D last fiscal, or about 6% of its revenue.
Over the last three years, it has spent $17 billion. “The 6% rule of the thumb
has been consistently true for years,“ Krishna told Corporate Dossier. In 2014,
IBM was issued 7,534 patents, the twenty-second year of overall US leadership
on that topic consecutively. “We have more patents than the six companies we
compete with put together,“ emphasises Krishna, who oversees 12 IBM labs
worldwide. In other words, IBM retains its supremacy in research alongside
Microsoft, Google, Accenture, Oracle, Amazon and HP combined. India Inc lagging
behind.
To put those numbers in context,
take a look at how much India Inc spends on research.Data from publicly listed
BSE 100 companies reveals that they spent an average of 1.32% of their net
turnover on R&D activities over the last three years. Of the 19 companies
that published R&D data for the year ending March 2014, ten companies spent
less than 0.5% on R&D.
So, why is India Inc not spending
enough on R&D?
India's economic history is one probable reason, argues RA Mashelkar, eminent scientist and former director general of Council of Scientific and Industrial Research. “Until 1991, we were a closed economy and there was no competition. Innovation takes root only when there is competition,“ he says. “In pharma, until 2005, there were no product patents, as the law didn't allow it. Only process patents existed. So, we used to copy molecules developed by Merck or Pfizer because of our strength in process chemistry and process engineering. After 2005, the incentive to copy has vanished and a number of companies have got into new molecule development.“ That impetus seems to be bearing fruit as 15 of the top 20 BSE 500 spenders on R&D in FY14 are pharma companies. However, Mashelkar cautions that R&D spends vary from sector to sector: “In retail, R&D is low but it is extremely vital in auto and pharma. So R&D spends in FMCG would be typically 0.5% of turnover; 2-3% in auto; and, could even be 10% in pharma.“ Indian IT companies are spending more on R&D as they move up the value chain. For instance, Infosys doubled it to 2.4% from 1.2% from FY09 to FY13; and TCS upped it to 1.2% from 0.2% in the same timeframe.
India's economic history is one probable reason, argues RA Mashelkar, eminent scientist and former director general of Council of Scientific and Industrial Research. “Until 1991, we were a closed economy and there was no competition. Innovation takes root only when there is competition,“ he says. “In pharma, until 2005, there were no product patents, as the law didn't allow it. Only process patents existed. So, we used to copy molecules developed by Merck or Pfizer because of our strength in process chemistry and process engineering. After 2005, the incentive to copy has vanished and a number of companies have got into new molecule development.“ That impetus seems to be bearing fruit as 15 of the top 20 BSE 500 spenders on R&D in FY14 are pharma companies. However, Mashelkar cautions that R&D spends vary from sector to sector: “In retail, R&D is low but it is extremely vital in auto and pharma. So R&D spends in FMCG would be typically 0.5% of turnover; 2-3% in auto; and, could even be 10% in pharma.“ Indian IT companies are spending more on R&D as they move up the value chain. For instance, Infosys doubled it to 2.4% from 1.2% from FY09 to FY13; and TCS upped it to 1.2% from 0.2% in the same timeframe.
“Indian CEOs need to take note of
research very closely since competition is now global,“ says Krishna, surveying
IBM's new-age client center at Delhi's tony Vasant Kunj area. “What drove
India's economy all this while was low cost offshoring or lower cost
programming in the IT industry but that model is probably running its course
because others (like Philippines and Malaysia) can copy it.“
The moonshot &
research So, how does IBM do it? To begin with, the 104-year old company has a
long history of innovation. In the 1960s, NASA commissioned IBM to help them
put a man on the moon. Between the Apollo 9 to 13 programs, the number of parts
comprising a complete spacecraft totted up to six million. In the movie Apollo
13, astronauts said they had a problem in space. “If you were sitting there
with engineers with books, how long do you think it would take them to find
something wrong in the spacecraft?“ asks Krishna. In effect, what got invented
was the first ever database.
Today, Krishna has about 3,000
researchers across a dozen locations around the globe, of which twothirds are
PhDs. There are about 300 researchers, from the field of mathematics alone, who
do everything from cryptography to optimisation of supply chains to new
analytical algorithms. “It helps our sustainability as a corporation because
the things these people do, will form the basis for business next year and the
year after that, and 10 years from now,“ says Krishna. If legacy is any
indicator, IBM is up there too with six Nobel laureates and as many Turing
awardees in its 104-year history. That's primarily because the company pushes
its people to be known in the science and engineering community, not just
inside IBM. That has translated into heavy contribution in science literature
with regular write-ups in Nature. Also, currently, it has 19 members from the American
Academy of Sciences, 23 members from the National Academy of Engineering,
Fellows from IEEE, besides a host of top-notch scientific community platforms.
Killing floors & Nobels
IBM has a killing floor too. Of the
12,000-odd homegrown ideas that the company came that the company came up with,
only 7,500 made it as patents. Others just fell by the wayside. At times,
Krishna points out, a single research project of a certain magnitude might
generate 30-100 patents. At the first stage, patents come out primarily from
the company's strategic lens--whether the idea aligns to the high value
innovation credo.The next level is all about gauging what difference it will
make. An incremental move is often abandoned for more pathbreaking research. In
the entire process, apart from keeping his ear to the ground, the 52-year-old
Krishna is aided by 12 lab leaders as well as four strategy leaders, who play a
role in guiding and selecting projects. Indian companies can draw several
lessons from Krishna's army of 3,000 researchers and how they are managed in an
environment that values freedom.For instance, the 2014 Nobel Prize winner in
Chemistry William E Moerner did his formative research in biophysics and
imaging of single molecules at IBM as a researcher where he worked for 15 years
before becoming a professor at Stanford.
Krishna says. Moerner started his
work because the fundamental question he was being asked at IBM was to store
information as far down as a single molecule. And he got the freedom to do a
bunch of work along those lines at the company's Almaden Research Center at San
Jose, California. And when he decided to move to academia, he was given the
freedom to do so.In the process, a two-way learning evolved where both Moerner
and IBM benefited.
The missing link
That industry-academia linkage is a
crucial missing piece in the India R&D puzze. “In R&D clusters around
the world, we not only find linkages with industry but also with reputed
institutes of higher education. So, we have to see the culture of excellence
and competitiveness in higher education itself,“ says Anu Madgavkar, Senior
Fellow, McKinsey Global Institute. The good news, however, is that Indian
companies beyond IT & pharma are looking at investing at increasing their
R&D spends. “We currently spend 1-1.5% of our sales on research and I want
to personally take that up to 3% in the next four years. That's because the
auto industry is becoming extremely intelligent,“ says Neeraj Kanwar, Vice
Chairman & MD, Apollo Tyres. & MD, Apollo Tyres.
The company has two R&D
centres--in Chennai and the Netherlands, employing about 150 and 130 people,
respectively.
For now, Krishna says the research
that has got him the most excited is some thing called Project Synapse, which
marries bio-sciences with digital technology to replicate cognition in
computers. “Today, you're lucky if a robot can speak to you...now imagine a
robot that can see you, recognise obstacles and move out of the way....(with
Synapse) we can begin to enable those things and help companies that want to
use robots for human interaction-elderly care, hospitality, industrial etc,“
sums up Krishna. India Inc.can draw inspiration from that project while
Darwinism knocks on its door.
By Moinak Mitra
|
CDET 10APR15
No comments:
Post a Comment